Review Article
Hypereosinophilic Syndrome: Two Case Reports of Contrasting Variants
Abstract
Two cases of hypereosinophilic syndrome that illustrate different variants are reported. Recognition of the specific variant is important because the treatments differ. Patients with hypereosinophilic syndrome should be monitored for evidence of a myeloproliferative process because treatment with tyrosine kinase inhibitors in these patients is effective and may prevent significant morbidity.
Key Points
* There are at least two variants of hypereosinophilic syndrome, illustrated by the case reports presented herein.
* It is important to determine which variant a patient has because of differing treatments.
* Tyrosine kinase inhibitors are effective in the myeloproliferative variant, and act by inhibiting a newly described gene fusion product called FIP1L1-PDGFR-α.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
